LinusBio Named “Fierce 15” Company of 2023 by Fierce Medtech

2024-03-05

突破性疗法

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--LinusBio, a leader in precision exposome sequencing, today announced its inclusion in Fierce Medtech's "Fierce 15" list for 2023. This annual special report highlights the most innovative private medtech companies that are making significant strides in the industry.

'We are deeply honored and humbled by this highly-regarded recognition'

LinusBio's inclusion underscores its unparalleled innovation in pioneering novel biomarkers. As highlighted in the feature, LinusBio’s proprietary platform introduces precision exposome sequencing that can facilitate discovery across various health conditions – from autism to gastrointestinal disorders to ALS to renal disease and cancers.

Historically, many conditions lacked reliable biological tests for diagnosis, progression monitoring, and clinical trial endpoints. LinusBio's platform generates data equivalent to over 500 liquid biopsies or blood samples, facilitating the mapping of molecular dynamics in human physiology in a time-dependent manner. LinusBio is leveraging this technology in pharma-sponsored trials and actively seeking additional partnerships to advance patient care further.

"We are deeply honored and humbled by this highly-regarded recognition," said Manish Arora, PhD, CEO and co-founder of LinusBio. "This acknowledgment stands as a testament to our unwavering dedication to advancing precision exposome medicine, while also highlighting the profound effect that our endeavors have on patients and their families. Looking ahead, we are committed to furthering our mission of delivering faster and more comprehensive diagnostics and treatments across a wide array of conditions and diseases."

StrandDx-ASD, the company's autism spectrum disorder diagnostic aid, set a new standard in diagnosis as the only objective biomarker test for the disorder, detected as early as one month of age. Boasting 80% to 90% accuracy, the test secured FDA Breakthrough Designation, signifying its potential to revolutionize early intervention strategies. The company intends to commence patient testing later this year.

The publication mentions that while the company is currently laser-focused on helping families whose children have ASD, LinusBio aims to eventually do the same in other conditions. The company’s program pipeline comprises novel biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, such as ADHD and ALS.

“Every year we celebrate a few of the most innovative toolmakers, whether they’re focused on helping clinicians reach, diagnose and treat the sick, or assisting the researchers chasing the next scientific and medical breakthroughs,” said Conor Hale, senior editor of Fierce Medtech. “These companies exemplify the ability of the medtech industry to turn cutting-edge ideas into meaningful outcomes and make them accessible on a large scale.”

To learn more about LinusBio visit LinusBio.com

About LinusBio

LinusBio (Linus Biotechnology Inc.) is a patient-centric, breakthrough science precision exposome medicine company headquartered in North Brunswick, NJ. The company’s program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology. For more information, visit www.linusbio.com.

About Fierce Medtech

Fierce Medtech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical technology. Top industry professionals rely on Fierce Medtech for an insider briefing on the day's top stories.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构